BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05147350 (RP-6306 in Advanced Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 15 Feb 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 26 Jun 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05147350
Acronym
MINOTAUR
Drug Name
RP-6306
Drug MoA
oral PKMYT1 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Advanced Solid Tumors
Human Patients
36
Sponsor
Repare Therapeutics
Phase
Phase 1

Prediction of , index 849

Prospective Prediction
Prediction Index
849
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
132 days in advance
Readout Data Interpretation
12% confirmed ORR (4/33) vs 30%-50% ORR for other X+ FOLFIRI combotherapies.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors
Phase
Phase 1
Status
Terminated
Enrollment
38
Lead sponsor
Debiopharm International SA
Conditions
Advanced Solid Tumor
Interventions
DRUG: RP-6306 (oral PKMYT1 inhibitor)
Design
Sequential · None
Primary purpose
Treatment
Start
2022-08-09
Primary completion
2025-02-12
Completion
2025-02-12
Results first posted
2025-08-20
Primary outcomes
  • Safety and Tolerability of RP 6306 in Combination With FOLFIRI (Start of treatment to 30 days post last dose. up to 1.5 years)
  • Recommended Phase 2 Dose (RP2D) and Schedule of RP-6306 in Combination With FOLFIRI (During 28 days (2 cycles) from the initiation of the study treatment)

NCT05147350 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials